Symbicort in Chronic Obstructive Pulmonary Disease - Full Text View

Symbicort in Chronic Obstructive Pulmonary Disease (SYMBOL)

This study has been completed.

First Received: January 29, 2008 Last Updated: February 8, 2008 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00611520

Purpose

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.

Condition
Chronic Obstructive Pulmonary Disease

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Symbicort in Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

MedlinePlus related topics: COPD (Chronic Obstructive Pulmonary Disease)

Drug Information available for: Symbicort

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Secondary Outcome Measures:

to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	64730
Study Start Date:	September 2005
Primary Completion Date:	December 2005 (Final data collection date for primary outcome measure)

Groups/Cohorts
1 Patients with COPD treated with budesonide/formoterol

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with COPD treated with budesonide/formoterol

Exclusion Criteria:

limitiations; possible risks; warnings; contraindications mentioned in the SPC.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00611520

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:

Kai Richter, MD

Medical Department AstraZeneca Germany

More Information

No publications provided

Responsible Party:	AstraZeneca Germany ( Dr Kai Richter )
Study ID Numbers:	1312005009
Study First Received:	January 29, 2008
Last Updated:	February 8, 2008
ClinicalTrials.gov Identifier:	NCT00611520 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:

treatment of COPD
related to the budesonide/formoterole therapy in patients with COPD.

Additional relevant MeSH terms:

Respiratory System Agents
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases
Therapeutic Uses

Lung Diseases
Respiration Disorders
Anti-Asthmatic Agents
Pharmacologic Actions
Pulmonary Disease, Chronic Obstructive

ClinicalTrials.gov processed this record on February 08, 2010